Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
BUSINESS Japan Generic Makers See Smaller Price Cuts in FY2024: Jiho Survey
March 7, 2024
-
BUSINESS Majority of Drug Makers “Somewhat Satisfied” with FY2024 Revision: Poll
March 7, 2024
-
BUSINESS Removal of PMP Company Indicators Most Popular Policy Change in FY2024 Reform: Poll
March 7, 2024
-
BUSINESS Eisai Pledges Up to US$15 Million for Alzheimer’s Blood Test Player
March 7, 2024
-
BUSINESS Takeda Triples Entyvio Production Capacity at Japan Site
March 7, 2024
-
BUSINESS Sumitomo Pharma to Ax 400 US Jobs as it Rejigs North American Biz
March 7, 2024
-
BUSINESS Ono Bags Cancer Drug License from South Korea’s NEX-I
March 7, 2024
-
REGULATORY Japan Cabinet OKs Bill to Amend Regenerative Medicine Safety Act, Clinical Trial Act
March 7, 2024
-
BUSINESS Tsumura Sees 24% Price Hike as Kampo Enjoys Boon in FY2024 Revision: Poll
March 6, 2024
-
BUSINESS Shionogi/Nagasaki University Enter New Phase of Malaria Collab, Aim for Clinical Trials
March 6, 2024
-
BUSINESS Taisho’s Nonprescription Anti-Obesity Drug to Hit Pharmacy Shelves on April 8
March 6, 2024
-
BUSINESS Mitsubishi, Daiichi Sankyo to Wind Up Diabetes Collab
March 6, 2024
-
REGULATORY New Govt Forum for Fighting Drug Loss Should Devise Strategies for Honebuto: LDP Members
March 6, 2024
-
BUSINESS Kyowa Pharma Joins Medipal-JWP JV, Now Sister Firm to Nichi-Iko
March 6, 2024
-
BUSINESS Shionogi, FunPep Enter Option Deal for Pollen Allergy Vaccine
March 6, 2024
-
REGULATORY Xocova Approval Meaningful, but Careful Use Should Continue: Minister
March 6, 2024
-
REGULATORY Opdivo Faces 15% Slash in Spillover, Re-Pricing to Hit 23 Drugs in FY2024 Revision
March 5, 2024
-
REGULATORY Drug Prices Cut by 4.67% in FY2024 Revision, 314 APIs to Keep Full Prices with PMP
March 5, 2024
-
REGULATORY Shionogi’s COVID Pill Xocova Lands Standard Approval in Japan
March 5, 2024
-
BUSINESS Astellas Kicks Off Japan PIII Studies for Hot Flash Med
March 5, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…